Changes in bone turnover and deoxypyridinoline levels in epileptic patients

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 1, 2000, Pages 47-50

  Telci, Ayşegül ^a,c   Çakatay, Ufuk ^a   Kurt, Betül Baykan ^a   Kayali, Refik ^b   Sivas, Ahmet ^a   Akçay, Tülay ^b   Gökyiǧit, Ayşen ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

25 Hydroxyvitamin D; Anticonvulsant therapy; Bone alkaline phosphatase; Bone turnover; Deoxypyridinoline; Osteocalcin

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; ANTICONVULSIVE AGENT; CALCIUM; CARBAMAZEPINE; DEOXYPYRIDINOLINE; OSTEOCALCIN; PHENOBARBITAL; PHENYTOIN;

ADULT; ARTICLE; BLOOD LEVEL; BONE TURNOVER; CONTROLLED STUDY; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; STATISTICS; URINE LEVEL;

EID: 0034027502     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2000.008     Document Type: Article

References (22)

1. Tohme JF, Seibel MJ, Silverberg SJ, Robins SP, Bilezikian JP. Biochemical markers of bone metabolism. Z Rheumatol 1991; 50:133-41.
2. Riis BJ. Biochemical markers of bone turnover II: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 95(suppl 5A):17-21.
3. Yoshimura N, Hashimoto T, Sakata K, Morioka S, Kasamatsu T, Cooper C. Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: the Taiji study. Calcif Tissue Int 1999; 65:198-202.
4. Kress BC, Mizrahi IA, Armour KW, Marcus R, Emkey RD, Santora AC. Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women. Clin Chem 1999; 45:1009-17.
5. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM. An evaluation of several biochemical markers of bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 1993; 91:1138-48.
6. Aloia JF, Cohn SH, Zanzi I, Abesamis C, Elis K. Hydroxyproline peptides and bone mass in postmenopausal and osteoporotic women. J Clin Endocrinol Metab 1978; 477:314-8.
7. Mitra D, Elvins DM, Collins AJ. Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures. J Rheumatol 1999; 26:2201-4.
8. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol 1999; 94:330-6.
9. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990; 8:87-96.
10. Seibel MJ, Robins SP, Bilezikian JP. Urinary pyridinium crosslinks of collagen: specific markers of bone resorption in metabolic bone disease. Trends in Endocrinol and Metab 1992; 3:263-70.
11. Ju HSJ, Leung S, Brown B, Stringer MA, Leigh S, Schrerrer C, et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem 1997; 43:1570-6.
12. Weisman Y, Fattal A, Eisenberg Z, Harel S, Spirer Z, Harell A. Decreased serum 24,25-dihydroxyvitamin D concentrations in children receiving chronic anticonvulsant therapy. Br Med J 1979; 2:521-3.
13. Çakatay U, Telci A, Kayali R, Akçay T, Sivas A, Aral A. Changes in bone turnover on deoxypyridinoline levels in diabetic patients. Diabetes Res Clin Pract 1998; 40:75-9.
14. Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993; 8:881-9.
15. 3 on bone metabolism in patients treated with phenobarbitone/phenytoin. Calcif Tissue Int 1985; 37:218-22.
16. Alderman CP, Hill CL. Abnormal bone mineral metabolism after long-term anticonvulsant treatment. Ann Pharmacother 1994; 28:47-8.
17. Bogliun G, Beghi E, Crespi V, Delodovici L, d'Amico P. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 1986; 74:284-8.
18. Christiansen C, Nielsen SP, Rødbro P. Anticonvulsant hypomagnesaemia. Brit Med J 1974; 1:198-9.
19. Jones G, Sambrook PN. Drug-induced disorders of bone metabolism. Incidence, management and avoidance. Drug Saf 1994; 10:480-9.
20. Ohishi T, Kushida K, Takahashi M, Kawana K, Yagi K, Kawakami K, et al. Urinary bone resorption markers in patients with metabolic bone disorders. Bone 1994; 15:15-20.
21. Ohishi T, Kushida K, Takahashi M, Kawana K, Inoue T, Yagi K. Analysis of urinary pyridinoline and deoxypyridinoline in patients undergoing long-term anticonvulsant drug therapy. Eur Neurol 1996; 36:300-2.
22. Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteocalcin secretion from rat osteosarcoma 17/2.8 cells in culture. Bone 1990; 11:309-12.